Haris Ali, MD, City of Hope

Medical experts discuss multidisciplinary approaches to GVHD.

Medical experts discuss the role of patient-reported outcomes in cGVHD.

Medical experts discuss emerging trends in chronic GVHD treatment.

Medical experts discuss the mechanism of action within axatilimab.

Medical experts discuss the recent updates presented at ASH 2023 and TANDEM 2024.

Medical experts discuss treatment selection for a specific clinical scenario.

Medical experts discuss considerations for third-line treatment in chronic GVHD.

Medical experts discuss the data that led to belumosudil’s FDA approval.

Medical experts discuss advanced therapies in cGVHD.

Medical experts discuss criteria for switching GVHD treatments and how to choose between available treatment options.

Medical experts discuss overall goals for cGVHD treatment as well as concerns with long-term corticosteroid use in treatment.

Medical experts discuss navigating chronic GVHD.

After a brief introduction, Shernan Holtan, MD, and Haris Ali, MD, discuss the distinction between acute and chronic graft-vs-host disease.

Haris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.

Haris Ali, MD, discusses the investigation of ruxolitinib and navitoclax combination therapy in myelofibrosis.

Expert perspectives on novel transplantation strategies to prevent or improve outcomes in graft-versus-host disease.

Brief insight on the FLIGHT and AGAVE-201 trials in chronic GVHD, which analyzed itacitinib, a JAK inhibitor, and axatilimab, a CSF1R inhibitor, respectively.

Considerations for novel treatment approaches with approved agents in combination or the frontline setting of chronic graft-vs-host disease.

Shared insight on how best to select ibrutinib, belumosudil, or ruxolitinib for patients with steroid-refractory chronic graft-vs-host disease.

Closing out his summation of ruxolitinib in chronic GVHD, Yi-Bin Chen, MD, considers how real-world use compares with the REACH3 trial results.

Comprehensive insight on the design and results of REACH3, which analyzed ruxolitinib as second-line therapy for chronic graft-vs-host disease.

In the context of chronic graft-vs-host disease, expert Yi-Bin Chen, MD, provides an overview of ruxolitinib’s mechanism of action.

Haris Ali, MD, shares insight on belumosudil, a ROCK2 inhibitor approved in the management of chronic graft-vs-host disease.

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

Expert perspectives on optimal treatment strategies for patients who develop steroid-refractory chronic graft-versus-host disease.

Yi-Bin Chen, MD outlines the definition of steroid-refractory vs steroid-dependent graft-vs-host disease.

A comprehensive breakdown of frontline treatment strategies for patients with newly diagnosed chronic graft-vs-host disease.

Insight on the identification of acute versus chronic graft-versus-host disease, including best diagnostic and risk stratification practices.

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft-versus-host disease, followed by insight on standard disease prevention practices.

Challenges and unmet needs in steroid-refractory GVHD and advice to community oncologists for the optimal management of disease.